Specific immunotherapy-indications and mode of action;Spezifische immuntherapie -indikation und wirkungsweise

Deutsches Arzteblatt International

Volumn 110, Issue 9, 2013, Pages 148-158

  Brehler, Randolf ^a   Klimek, Ludger ^b   Kopp, Matthias Volkmar ^c   Virchow, Johann Christian ^d  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Center for Rhinology and Allergology   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; DESLORATADINE; MOMETASONE FUROATE; MONTELUKAST; RECOMBINANT ALLERGEN;

ADJUVANT THERAPY; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; ARTICLE; CLINICAL EVALUATION; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; INFORMATION RETRIEVAL; PHARMACEUTICAL CARE; PUBLICATION; RESPIRATORY SYSTEM; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION; EVIDENCE BASED MEDICINE; IMMUNOLOGY; PREVALENCE; PROCEDURES; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME;

CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; EVIDENCE-BASED MEDICINE; HUMANS; PREVALENCE; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME;

EID: 84906329074     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2013.0148     Document Type: Article

References (40)

1. Asher MI, Montefort S, Björkstén B, et al.: Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006; 368: 733-43.
2. Björkstén B, Clayton T, Ellwood P, Stewart A, Strachan D: ISAAC Phase III Study Group Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol 2008; 19: 110-24.
3. Ring J, Bachert C, Bauer C P, Czech W (eds.): Weiβbuch Allergie in Deutschland. München: Urban & Vogel 2009.
4. Maurer M, Zuberbier T: Undertreatment of rhinitis symptoms in Europe: Findings from a cross-sectional questionnaire survey. Allergy 2007; 62: 1057-63.
5. FORSA Umfrage 2012: Www.derma.de/fileadmin/eingang/FOR SA-Allergien.de
6. Jacobsen L, Niggemann B, Dreborg S, et al.: (The PAT investigator group). Specific immunotherapy has long-Term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007; 62: 943-8.
7. Calderon MA, Gerth van Wijk R, Eichler I, et al.: Perspectives on allergen-specific immunotherapy in childhood: An EAACI position statement. Pediatr Allergy Immunol 2012; 23: 300-6.
8. Zuberbier T, Lötvall J: Allergies have a socioeconomic impact: A model calculation. Allergy 2008; 63 (Suppl. 88): 612-21.
9. Graf von der Schulenburg JM, Greiner W, Molitor S, Kielhorn A: Medizinische Ökonomie -Kosten der Asthmatherapie nach Schweregrad, Eine empirische Untersuchung. Medizinische Klinik 1996; 91: 670-6.
10. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001936. DOI: 10.1002/14651858.CD001936
11. Radulovic S, Calderon MA, Wilson D, Durham S: Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010; (12): CD002893
12. Abramson MJ, Puy RM,Weiner JM: Injection allergen immunotherapy for asthma. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD001186. DOI: 10.1002/14651858.CD001186.pub2.
13. Kleine-Tebbe J, Bufe A, Ebner C, et al.: Leitlinien der Deutschen Gesellschaft Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA), der Gesellschaft für pädiatrische Allergologie und Umweltmedizin (GPA), der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI) und der Schweizerischen Gesellschaft für Allergologie und Immunologie (SGAI). Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE vermittelten allergischen Erkrankungen. Allergo J 2009; 18: 508-37.
14. Calderon MA, Larenas D, Kleine-Tebbe J, et al.: European Academy of Allergy and Clinical Immunology task force report on 'dose-response relationship in allergen-specific immunotherapy'. Allergy 2011; 66: 1345-59
15. Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E, et al.: Local immunotherapy. Allergy 1998; 53: 933-44.
16. 2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010; 65: 1525-30.
17. Bousquet J, Lockey R, Malling HJ: WHO position paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. Allergy 1998; 53(Suppl 54): 1-42.
18. Canonica GW, Bousquet J, Casale T, et al.: Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64 (Suppl 91): 1-59.
19. Walker SM, Durham SR, Till SJ, et al.: British Society for Allergy and Clinical Immunology; Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011; 41: 1177-200.
20. Guidline on allergen products: Production and quality issues des comittee for medical products for human use (CHMP): Www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideli ne/2009/09/WC500003333.pdf
21. Guidline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases des comittee for medical products for human use (CHMP): Www.emea.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003605.pdf
22. Matricardi PM, Kuna P, Panetta V, Wahn U, Narkus A: Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: A comparison based on meta-Analyses. J Allergy Clin Immunol. 2011; 128: 791-9.
23. Fujita H, Soyka MB, Akdis M, Akdis CA: Mechanisms of allergenspecific immunotherapy. Clin Transl Allergy 2012; 2: 2.
24. James LK, Shamji MH, Walker SM, et al.: Long-Term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011; 127: 509-16.
25. Haugaard L, Dahl R, Jacobsen L.: A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: Clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91: 709-22.
26. Didier A, Malling HJ, Worm M, Horak F, et al.: Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120: 1338-45.
27. Chapman MD, Ferreira F, Villalba M, et al; CREATE consortium. The European Union CREATE project: A model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol 2008; 122: 882-9.
28. Pfaar O, Robinson DS, Sager A, Emuzyte R. Immunotherapy with depigmented-polymerized mixed tree pollen extract: A clinical trial and responder analysis. Allergy 2010; 65: 1614-21.
29. Durham SR, Emminger W, Kapp A, et al.: SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129: 717-25.
30. Ott H, Sieber J, Brehler R, Fölster-Holst R, Kapp A, Klimek L, Pfaar O, Merk H.: Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: The ECRIT study. Allergy 2009; 64: 1394-401.
31. Valovirta E, Berstad AK, de Blic J, et al.: GAP investigators. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Ther 2011; 33: 1537-46.
32. Paul-Ehrlich Institut: Therapieallergene www.pei.de/DE/arzneimittel/allergene/therapieallergene/therapieallergene-inhalt.html. Last accessed on 12 February 2013
33. Calderón MA, Cox L, Casale TB, Moingeon P, Demoly P: Multiple-Allergen and single-Allergen immunotherapy strategies in polysensitized patients: Looking at the published evidence. J Allergy Clin Immunol 2012; 129: 924-34.
34. Valenta R, Laffer S, Vrtala S, et al.: Recombinant allergens. Steps on the way to diagnosis and therapy of type I allergy. Adv Exp Med Biol 1996; 409: 185-96.
35. Schmid-Grendelmeier P: Recombinant allergens. For routine use or still only science? Hautarzt 2010; 61: 946-53.
36. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP: Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006; 61: 198-201.
37. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A, Study Group: Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-Adsorbed six-grass pollen allergoid. Allergy 2005; 60: 801-7.
38. DuBuske LM, Frew AJ, Horak F, et al.: Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011; 32: 239-47.
39. Pfaar O, Urry Z, Robinson DS, et al.: A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy 2012; 67: 272-9.
40. Pfaar O, Robinson DS, Sager A, Emuzyte R: Immunotherapy with depigmented-polymerized mixed tree pollen extract: A clinical trial and responder analysis. Allergy 2010; 65: 1614-21.